Fennec Pharmaceuticals Strengthens Executive Leadership Team With Three Key Appointments To Accelerate The Company’S Next Stage Of Growth

( MENAFN - GlobeNewsWire - Nasdaq) ~ Pierre S. Sayad, PhD, M.S.

, Appointed Chief Medical Officer ~ ~ Terry Evans Appointed Chief Commercial Officer ~ ~ Christiana Cioffi, MBA, Appointed Chief Strategy Officer ~ RESEARCH TRIANGLE PARK, N.C., Oct.

28, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty Pharmaceutical company, today announced that it has strengthened its executive leadership team with the appointments of Pierre S. Sayad, PhD, M.

S., as chief medical officer, Terry Evans as chief commercial officer and Christiana Cioffi, MBA, as chief strategy officer, all of which become effective immediately. “Building an experienced, multi-talented executive leadership team is a critical step for Fennec as we embark on a new chapter in the organization's evolution, and I am delighted to welcome Pierre, Terry and Christiana to Fennec,” said Jeffrey S.

Hackman, chief executive officer and director of Fennec Pharmaceuticals.“Pierre, Terry and Christiana are seasoned biopharmaceutical industry executives with proven clinical, commercial, operational, and oncology market expertise. We believe that their leadership, combined with Fennec's talented employee base, will significantly accelerate our ability to build upon and seamlessly execute our commercialization strategy for PEDMARK, the first and only therapy approved in the U.

S. and Europe to reduce the risk of ototoxicity, or permanent hearing loss, associated with cispl.